Kiani Maziar Hasanzadeh, Shayesteh Ali Akbar, Ahmadzadeh Ahmad
Department of Internal Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Gastroenterology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
J Family Med Prim Care. 2019 Jun;8(6):2003-2007. doi: 10.4103/jfmpc.jfmpc_212_18.
Chemotherapy-induced nausea and vomiting (CINV) is a condition that occur in most patients. This study aimed to investigate the effect of gabapentin capsules on the reduction of chemotherapy-induced nausea and vomiting in patients admitted in the hematological ward for adult patients with platinum-based treatment.
The present study was a randomized clinical trial, which consisted of a control group and an experimental one. The study population consisted of 126 women and men with colonic and gastric cancer who were admitted to Ahwaz Shafa Hospital of adult hematology ward. Of these, 120 subjects were eligible to enter the study. Immediately after chemotherapy, gabapentin capsules were taken. Up to 72 hours later, nausea and vomiting were compared. Descriptive statistics was used to investigate the demographic characteristics. Paired -test, independent -test and ANOVA were used to compare the results.
The results showed that most of the patients had gastric cancer in the experimental (70%) and control group (66.66%). The results also showed that chemotherapy-induced nausea and vomiting in gabapentin recipient group was different from the placebo group. Accordingly, chemotherapy induced nausea and vomiting in gabapentin group was lower than the placebo group.
Post-operative nausea and vomiting is an unpleasant experience. Today, the patients find it worse than pain, and they believe it is hard to afford the cost of treatment. Gabapentin seems to be a good drug for reducing nausea and vomiting.
化疗引起的恶心和呕吐（CINV）是大多数患者都会出现的一种情况。本研究旨在调查加巴喷丁胶囊对减少血液科病房接受铂类治疗的成年患者化疗引起的恶心和呕吐的效果。
本研究为一项随机临床试验，包括一个对照组和一个试验组。研究对象为126名患有结肠癌和胃癌的成年男女，他们被收治于阿瓦士沙法医院成人血液科病房。其中，120名受试者符合进入研究的条件。化疗后立即服用加巴喷丁胶囊。在724小时后，比较恶心和呕吐情况。使用描述性统计来研究人口统计学特征。采用配对t检验、独立t检验和方差分析来比较结果。
结果显示，试验组（70%）和对照组（66.66%）中大多数患者患有胃癌。结果还表明，加巴喷丁接受组化疗引起的恶心和呕吐与安慰剂组不同。因此，加巴喷丁组化疗引起的恶心和呕吐低于安慰剂组。
术后恶心和呕吐是一种不愉快的经历。如今，患者认为它比疼痛更糟糕，并且他们认为难以承受治疗费用。加巴喷丁似乎是一种减轻恶心和呕吐的良药。
